Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Asthma treatment costs using inhaled corticosteroids.

S S Holzer1, L Engelhart, W H Crown

  • 1American Academy of Otolaryngology-Head and Neck Surgery Foundation, Washington DC, USA.

The American Journal of Managed Care
|May 7, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Healthcare expenditure in patients treated with venlafaxine or selective serotonin reuptake inhibitors for depression and anxiety.

International journal of clinical practice·2002
Same author

Long-term costs of treatment for depression: impact of drug selection and guideline adherence.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2001
Same author

Hospitalization and total medical costs for privately insured persons with schizophrenia.

Administration and policy in mental health·2001
Same author

Antidepressant selection and economic outcome: a review of methods and studies from clinical practice.

The British journal of psychiatry. Supplement·2001
Same author

Gender-specific effects of modifiable health risk factors on coronary heart disease and related expenditures. HERO Research Committee. Health Enhancement Research Organization.

Journal of occupational and environmental medicine·2000
Same author

Economic outcomes associated with tricyclic antidepressant and selective serotonin reuptake inhibitor treatments for depression.

Acta psychiatrica Scandinavica. Supplementum·2000
Same journal

Prescription drug prior authorization: costs to pharmacies and physicians.

The American journal of managed care·2026
Same journal

Combined pharmacotherapy and psychotherapy impact on opioid use disorder treatment.

The American journal of managed care·2026
Same journal

The societal costs of food insecurity: implications for managed care strategies.

The American journal of managed care·2026
Same journal

Availability of hospital financial assistance documents in non-English languages.

The American journal of managed care·2026
Same journal

Real-world weight loss with injectable semaglutide vs dulaglutide for diabetes.

The American journal of managed care·2026
Same journal

Social needs screening and supplemental benefits in Medicare Advantage.

The American journal of managed care·2026
See all related articles

Triamcinolone acetonide (Azmacort) users incurred higher asthma healthcare costs than beclomethasone dipropionate (Vanceril/Beclovent) and flunisolide (Aerobid) users. These findings highlight economic differences in inhaled corticosteroid therapies for asthma management.

Area of Science:

  • Pulmonary Medicine
  • Health Economics
  • Pharmacoeconomics

Background:

  • Asthma is a prevalent chronic respiratory disease with significant economic burden in the US.
  • Inhaled corticosteroids (ICS) are cornerstone therapies for asthma management.
  • Understanding the economic impact of different ICS is crucial for healthcare resource allocation.

Purpose of the Study:

  • To compare healthcare utilization expenditures among three inhaled corticosteroids: beclomethasone dipropionate, flunisolide, and triamcinolone acetonide.
  • To identify potential economic benefits associated with specific ICS therapies in asthma patients.

Main Methods:

  • Retrospective analysis of 4,441 patients' claims data from 1990-1993.
  • Utilized inpatient, outpatient, and prescription drug claims from The MEDSTAT Group's MarketScan database.

Related Experiment Videos

  • Employed multivariate linear regression to control for demographic and clinical factors.

    • Main Results:

    • After excluding study drug costs, triamcinolone acetonide (Azmacort) users had higher total asthma healthcare expenditures than beclomethasone dipropionate (Vanceril/Beclovent) and flunisolide (Aerobid) users.
    • Including study drug costs, both triamcinolone acetonide and flunisolide users showed higher expenditures compared to beclomethasone dipropionate users.
    • No significant expenditure differences were found between beclomethasone dipropionate formulations (Vanceril and Beclovent).

    Conclusions:

    • Triamcinolone acetonide and flunisolide may be associated with higher overall asthma-related healthcare costs compared to beclomethasone dipropionate.
    • Factors such as patient age, drug switching patterns, and comorbidities influence total asthma treatment expenditures.
    • Further pharmacoeconomic research is warranted to optimize ICS selection for cost-effectiveness in asthma care.